BRAIN Biotech AG
- WKN: 520394
- ISIN: DE0005203947
- Land: Deutschland
Nachricht vom 15.09.2021 | 21:48
BRAIN Biotech AG: BRAIN Biotech AG has successfully completed 10% cash capital increase from authorised capital with exclusion of statutory subscription rights
BRAIN Biotech AG / Key word(s): Capital Increase
Disclosure of inside information in accordance with Article 17 MAR of the Regulation (EU) No 596/2014
NOT FOR DIRECT OR INDIRECT PUBLICATION, DISTRIBUTION OR RELEASE IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA AND JAPAN OR ANY JURISDICTION IN WHICH OFFERS OR SALES OF THE SECURITIES WOULD BE PROHIBITED BY APPLICABLE LAW.
BRAIN Biotech AG has successfully completed 10% cash capital increase from authorised capital with exclusion of statutory subscription rights; placement price set at 9.85 Euro per new share
It is intended that the New Shares shall be admitted to trading without a prospectus on 17 September 2021, and shall be included in the quotation of the existing shares on the regulated market of the Frankfurt Stock Exchange (Prime Standard) on 21 September 2021.
BRAIN Biotech AG ("BRAIN") is a leading European specialist in industrial biotechnology. As a technology provider and developer of bio-based products and solutions for nutrition, health and the environment, the company supports the biologization of industry and contributes to a more sustainable economy. BRAIN is the parent company of the BRAIN Group. Two pillars form BRAIN Group's business: The BioScience segment includes contract research for renowned industrial partners as well as an incubator for the development of the company's own highly innovative products. In the BioIndustrial segment, the company focuses on specialty business in the production and refinement of enzymes, microorganisms and bioactive natural products and the respective distribution.
This document and the information contained herein are not for distribution in or into the United States of America (including its territories and possessions, any state of the United States of America and the District of Columbia) (the "United States"), Canada, Australia or Japan. This document does not constitute, or form part of, an offer to sell, or a solicitation of an offer to purchase, any securities of BRAIN Biotech AG in the United States. The New Shares of BRAIN Biotech AG have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. BRAIN Biotech AG does not intend to conduct a public offering of equity securities in the United States. Any sale in the United States of the securities mentioned in this communication will be made solely to "qualified institutional buyers" as defined in Rule 144A under the Securities Act.
The offer referred to herein, when made in member states of the European Economic Area and the United Kingdom, is only addressed to and directed to "qualified investors" within the meaning of Article 2(e) the Prospectus Regulation ("Qualified Investors"). For these purposes, the expression "Prospectus Regulation" means Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC, and includes any relevant delegated regulations.
For readers in the United Kingdom, this announcement is only being distributed to and is only directed at Qualified Investors who are (i) outside the United Kingdom or (ii) investment professionals falling within Article 19(5) ("Investment professionals") of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or (iii) certain high value persons and entities who fall within Article 49(2)(a) to (d) ("High net worth companies, unincorporated associations etc.") of the Order; or (iv) any other person to whom it may lawfully be communicated (all such persons in (i) to (iv) together being referred to as "relevant persons"). The New Shares are expected to only be available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such New Shares will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this announcement or any of its contents.
This announcement contains forward-looking statements that are subject to certain risks and uncertainties. The future financial results can significantly differ from the currently anticipated results as a result of various risks and uncertainties, including changes in the business, financial and competitive landscape, uncertainties related to legal disputes or investigations and the availability of funds. BRAIN Biotech AG assumes no obligation to update the forward-looking statements included in this announcement. Forward-looking statements speak only as of the date they are made.
Information to Distributors of New Shares
For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the New Shares.
Each distributor is responsible for undertaking its own target market assessment in respect of the New Shares and determining appropriate distribution channels.
BRAIN Biotech AG
Head IR & Sustainability
Darmstädter Str. 34-36
|Company:||BRAIN Biotech AG|
|Darmstädter Straße 34-36|
|Phone:||+49 (0) 62 51 / 9331-0|
|Fax:||+49 (0) 62 51 / 9331-11|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1233738|
|End of Announcement||DGAP News Service|
BRAIN Biotech AG: Release according to Article ...
BRAIN Biotech AG successfully placed new share ...
BRAIN Biotech AG: BRAIN Biotech AG has success ...
BRAIN Biotech AG resolves on a cash capital in ...
BRAIN Biotech AG resolves on a 10% cash capita ...
IPO im Fokus
MIT SICHERHEIT AUFS PARKETT.
UNSER BÖRSENGANG ZUR
Grundkapital (vor IPO): 3.120.000 EUR
Angebotene Aktien: bis zu 690.000 Aktien
Zeichnungsfrist: 11.10.2021 bis voraus. 25.10.2021
Bookbuildingspanne: 3,30 bis 3,60 Euro
Börse: Börse Düsseldorf
Rechtlich maßgeblicher Wertpapierprospekt auf sdm-se.de
Event im Fokus
10. Juni 2021:Fachkonferenz Immobilien
14./15. Juli 2021: Fachkonferenzen Beteiligungsgesellschaften & Consumer/Leisure
13./14. Oktober 2021: Fachkonferenzen Finanzdienstleistungen/Technologie
10./11. November 2021: Fachkonferenzen Software/IT & Branchenmix
„Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen entscheidet sich ca. 5 Wochen vor dem Termin, in welcher Form die Konferenzen stattfinden.“
IIF – International Investment Forum
Wann: 14. Oktober 2021, 9:45 - 18:00 Uhr
Wo: Online Live-Event via ZOOM
Wer: börsennotierte Unternehmen aus den Small- und Midcap-Segmenten aller Welt
Branchen: Technologie, Rohstoffe, Sicherheit, Medizin, Logistik und Raumfahrt
Für: Alle Investoren & Presse
Weitere Informationen: www.ii-forum.com
Der AKTIONÄR News
15. Oktober 20:41 Schlussglocke: Dow Jones mit starkem Wochenabschluss - Goldman Sachs ...
15. Oktober 18:59 Johnson & Johnson: FDA stimmt zu - Aktie dank Booster-Impfung zur ...
15. Oktober 18:14 Netflix: "Top-Performer der kommenden Monate"
15. Oktober 17:58 Lufthansa: Das passt
News im Fokus
Delivery Hero verstärkt seine Präsenz in Zentralamerika und der Karibik durch die Übernahme der Restaurant- und Lebensmittellieferdienste von hugo
14. Oktober 2021, 08:00
Original-Research: 2G Energy AG (von First Berlin Equity Research GmbH): Hinzufügen
15. Oktober 2021